The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

First Steps warns moviegoers to silence their cell phones, and sees H.E.R.B.I.E. speak for the first time...which isn't quite ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

PFAS are found in multiple everyday products, such as cosmetics, outdoor clothing and coated pans. This is because of their ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

Single-cell biology has transformed how we decode cellular heterogeneity, but a new frontier is emerging: understanding what ...

Dr. Stephen Hauser has spent over 40 years of his professional career studying and researching Multiple Sclerosis. The ...